PDCD1 and cancer: In the KEYNOTE-012 Phase 1b study (NCT01848834), the safety and anti-cancer activity of pembrolizumab, a humanized monoclonal antibody specific for PD-1, was evaluated in patients with advanced TNBC, urothelial cancer, head and neck cancer, and gastric cancer [15].